Liraglutide

Overview

Liraglutide is a once-daily injectable GLP-1 receptor agonist that mimics the incretin hormone GLP-1 to enhance glucose-dependent insulin secretion, slow gastric emptying, and reduce appetite. It is one of the better-evidenced peptides on the market: it is FDA-approved and supported by large Phase 3 trials, sold as Victoza for type 2 diabetes and as Saxenda for chronic weight management. Approval is indication-specific, and as with any approved drug, off-label use is not an endorsement. It is a true peptide analog of human GLP-1.

Commonly Reported Uses

These are uses commonly discussed or marketed by users and vendors — not a list of proven or approved benefits, and not a recommendation.

• Type 2 diabetes glycemic control (FDA-approved indication — Victoza)
• Chronic weight management in obesity/overweight with comorbidity (FDA-approved indication — Saxenda)
• Reduction of major adverse cardiovascular events in type 2 diabetes with established CV disease (FDA-approved indication — Victoza)

What to Track

Data points you and your clinician might monitor. For observation only — not a diagnostic protocol.

• Smart scale — weight and body-fat % trend
• Labs — HbA1c and fasting glucose for glycemic response
• Labs — lipid panel if a clinician is monitoring cardiometabolic risk
• MyFitnessPal — calories and protein g/kg, since appetite suppression can reduce intake
• Subjective — daily nausea, appetite, and GI tolerability check-ins

Sources & References

1. [1]Liraglutide — Wikipedia
2. [2]Liraglutide: Uses, Dosage, Side Effects, Warnings — Drugs.com
3. [3]FDA Approves First Generic GLP-1 Liraglutide for Weight Loss — Drug Topics